Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as C$0.32 and last traded at C$0.31, with a volume of 982216 shares trading hands. The stock had previously closed at C$0.28.
Hemostemix Price Performance
The company has a market capitalization of C$32.67 million, a PE ratio of -18.75 and a beta of 0.20. The company’s 50 day simple moving average is C$0.13 and its 200 day simple moving average is C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Differences Between Momentum Investing and Long Term Investing
- Bloom Energy: Powering the Future With Decentralized Energy
- What Investors Need to Know to Beat the Market
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
